Buy Alfusin-D (Alfuzosin, Dutasteride) online

Buy Alfusin-D (Alfuzosin / Dutasteride) for the treatment of BPH in men
Cheap qualitative Alfuzosin with Dutasteride 10 mg / 0.5 mg pills online



HOW AND WHERE TO BUY ALFUSIN-D, DUTALFA, AFDURA (ALFUZOSIN WITH DUTASTERIDE) 10 MG / 0.5 MG CAPSULES OR TABLETS ONLINE:

ALFUSIN-D PRESCRIBING INFORMATION

COMPOSITION

Alfusin-D Tablets

Each film-coated tablet contains:
Alfuzosin Hydrochloride BP 10 mg (as extended-release)
Dutasterid 0.5 mg
Colour: Titanium Dioxide IP


DESCRIPTION

Alfusin-D tablets contain alfuzosin hydrochloride and dutasteride as active pharmaceutical ingredients (APIs). Alfuzosin HCl is a selective alpha1-adrenoreceptor blocking agent and exhibits selectivity for alpha1-adrenergic receptors in the lower urinary tract. Blockade of these adrenoreceptors can cause smooth muscles in the bladder neck and prostate to relax, resulting in an improvement in urine flow and a reduction in the symptoms of benign prostatic hyperplasia (BPH).

Dutasteride is a synthetic 4-azasteroid compound that is a selective inhibitor of both type I and type II isoforms of steroid 5 alpha-reductase (5AR), an intracellular enzyme that converts testosterone to 5 alpha-dihydrotestosterone (DHT). DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. The type II isoenzyme is primarily active in the reproductive tissues while the type I isoenzyme is also responsible for testosterone conversion in the skin and liver. Alfusin-D tablets act on both the dynamic and the static components of BPH.


DOSAGE FORM

Film-coated oral tablet


PHARMACOLOGY

  • Alfusin-D pharmacodynamics
  • Alfusin-D pharmacokinetics


    INDICATIONS

    Alfusin-D tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
    The tablets are not intended for use as an anti-hypertensive drug.
    Dutasteride is not approved for the prevention of prostate cancer.


    DOSAGE AND ADMINISTRATION

    The recommended dosage of Alfusin-D is one tablet daily, to be taken immediately after the same meal each day. The tablet should be swallowed whole and should not be chewed or crushed.

    Special Populations

    Renal Impairment

    Caution should be exercised when alfuzosin is administered in patients with severe renal impairment (creatinine clearance No dose adjustment is necessary for dutasteride in patients with renal impairment.

    Hepatic Impairment

    Alfuzosin is contraindicated for use in patients with moderate or severe hepatic impairment. Although the pharmacokinetics of alfuzosin have not been studied in patients with mild hepatic impairment, caution should be exercised when alfuzosin is administered to such patients.

    The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied. Because dutasteride is extensively metabolized, exposure could be higher in hepatically impaired patients.


    CONTRAINDICATIONS OF ALFUSIN-D

    Alfusin-D tablets are contraindicated for use in women of childbearing potential and during pregnancy.

    These tablets are contraindicated for use in paediatric patients.

    The drug in tablets should not be used in patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C) since alfuzosin hydrochloride blood levels are increased in these patients.

    Alfusin-D tablets should not be co-administered with potent CYP3A4 inhibitors such as ketoconazole, itraconazole and ritonavir, since alfuzosin hydrochloride blood levels are increased.

    Tablets of this medication are contraindicated in patients with known hypersensitivity to alfuzosin hydrochloride (e.g., urticaria and angioedema) or to dutasteride (e.g., serious skin reactions, angioedema) or any component of Alfusin-D tablets.


    PRECAUTIONS AND WARNINGS

  • Alfusin-D warnings and precautions


    UNDESIRABLE EFFECTS

  • Alfusin-D adverse effects


    OVERDOSAGE

    Overdosage with Alfusin-D tablets could potentially lead to hypotension due to the alfuzosin hydrochloride component. In case of hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, then administration of intravenous fluids should be considered. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Alfuzosin hydrochloride is 82-90% protein-bound; therefore, dialysis may not be of benefit.

    In volunteer studies, single doses of dutasteride up to 40 mg (80 times the therapeutic dose) for 7 days have been administered without significant safety concerns. In a clinical study, daily doses of 5 mg (10 times the therapeutic dose) were administered to 60 subjects for 6 months with no additional adverse effects to those seen at therapeutic doses of 0.5 mg.

    There is no specific antidote for dutasteride. Therefore, in cases of suspected overdosage, symptomatic and supportive treatment should be given as appropriate, taking the long half-life of dutasteride into consideration.


    STORAGE AND HANDLING INSTRUCTIONS

    Store this medication in a cool and dry place, protected from light.


    PACKAGING INFORMATION

    Alfusin-D

    Strip of 10 tablets

    Recent posts:

  • Buy Alfusin-D (Alfuzosin, Dutasteride) Online

    Copyright © Buy Alfusin-D (Alfuzosin with Dutasteride) Online